Trial Profile

Phase 3 study of SNA 001

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 08 Dec 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SNA 001 (Primary)
Indications Thyroid cancer
Focus Adverse reactions; Therapeutic Use

Most Recent Events

08 Dec 2021 New trial record
29 Apr 2020 According to a SmartNuclide Biopharma media release, first patient has been enrolled in April.
12 Feb 2020 According to a SmartNuclide Biopharma media release, The experimental leader unit is Zhongshan Hospital Affiliated to Fudan Universityvand the main researcher is Professor Hongcheng Shi. The ethical approval of SNA001 was approved by the leader unit on 26th November 2019.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com